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High prevalence of bronchiectasis is linked
to HTLV-1-associated inflammatory disease
Shohreh Honarbakhsh1* and Graham P Taylor1,2
Abstract
Background: Human T-lymphotropic virus type 1 (HTLV-1), a retrovirus, is the causative agent of HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukaemia/lymphoma (ATLL). The reported
association with pulmonary disease such as bronchiectasis is less certain.
Methods: A retrospective case review of a HTLV-1 seropositive cohort attending a national referral centre. The
cohort was categorised into HTLV-1 symptomatic patients (SPs) (ATLL, HAM/TSP, Strongyloidiasis and HTLV
associated inflammatory disease (HAID)) and HTLV-1 asymptomatic carriers (ACs). The cohort was reviewed for
diagnosis of bronchiectasis.
Result: 34/246 ACs and 30/167 SPs had been investigated for respiratory symptoms by computer tomography (CT)
with productive cough +/- recurrent chest infections the predominant indications. Bronchiectasis was diagnosed in
one AC (1/246) and 13 SPs (2 HAID, 1 ATLL, 10 HAM/TSP) (13/167, RR 19.2 95 % CI 2.5-14.5, p = 0.004) with high
resolution CT. In the multivariate analysis ethnicity (p = 0.02) and disease state (p < 0.001) were independent
predictors for bronchiectasis. The relative risk of bronchiectasis in SPs was 19.2 (95 % CI 2.5-14.5, p = 0.004) and in
HAM/TSP patients compared with all other categories 8.4 (95 % CI 2.7-26.1, p = 0.0002). Subjects not of
African/Afro-Caribbean ethnicity had an increased prevalence of bronchiectasis (RR 3.45 95 % 1.2-9.7, p = 0.02).
Conclusions: Bronchiectasis was common in the cohort (3.4 %). Risk factors were a prior diagnosis of HAM/TSP and
ethnicity but not HTLV-1 viral load, age and gender. The spectrum of HTLV-associated disease should now include
bronchiectasis and HTLV serology should be considered in patients with unexplained bronchiectasis.
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Author summary
The spectrum of disease associated with HTLV-1 has
not been completely defined. The association between
HTLV-1 and pulmonary conditions is less well docu-
mented and clinically recognised. Bronchiectasis has
been reported amongst Australian aborigines infected
with HTLV-1. We have observed a high rate of bronchi-
ectasis in a UK HTLV-1 infected cohort. We have shown
that patients with non-pulmonary HTLV-1-associated
disease, particularly inflammatory disease, are more
likely to have an additional diagnosis of bronchiectasis
than asymptomatic carriers and postulate that the same
dysregulated hyper-inflammatory response seen in
HTLV-associated myelopathy/tropical spastic paraparesis
may play a role in this setting. Our findings highlight the
importance of screening HTLV-1 infected patients, par-
ticularly those with inflammatory disease, for pulmonary
disease.
Background
The human T-lymphotropic virus type-1 (HTLV-1), a
retrovirus, has been estimated to infect at least 5-10 mil-
lion people worldwide with the highest prevalence re-
ported in Japan, Africa, The Caribbean and South
America [1]. It is the causative agent of adult T-cell
leukaemia/lymphoma (ATLL) [2], with a life-time risk of 3
– 7 % [3], of HTLV-1-associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP) [4, 5] affecting up to 4 % of
carriers [6] and of HTLV-1-associated uveitis [7]. However
the full spectrum and risk of developing a HTLV-1-
associated disease remains uncertain with a much broader
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list of affected systems reported including: polymyositis [8],
arthropathy [9], Sjögren’s syndrome (keratoconjunctivitis
sicca) [10, 11], thyroiditis [12] and infective dermatitis [13].
It is understood that HAM/TSP is secondary to a dysfunc-
tional inflammatory response [14] to high HTLV-1 pro-
viral load (VL) [15, 16] and although less studied a similar
relationship between other inflammatory conditions (uveitis
[17], polymyositis [18]) and VL has been observed.
Although less recognised associations between HTLV-
1 and pulmonary conditions have been reported: pa-
tients with HTLV-1 have increased lymphocytes in bron-
choalveolar lavage fluid (BAL) which correlates with
HTLV-1 VL in both the BAL and peripheral blood
mononuclear cells (PBMC) [19]; patients with HAM/
TSP [20] or HTLV-1-associated uveitis [21] have been
shown to have significantly higher BAL lymphocyte
counts than HTLV asymptomatic carriers (ACs); hist-
ology of surgical or transbronchial biopsies has revealed
lymphocytic infiltration along bronchioles and broncho-
vascular bundles [22]; IL-2 receptor levels are markedly
elevated in BAL from patients with HAM/TSP com-
pared to ACs [23]; high frequency of activated T cells
and increased MIP-1alpha and IP-10 concentrations
have been found in BAL from patients with HTLV-1 and
cryptogenic fibrosing alveolitis [24].
To date the most comprehensive report of pulmonary
imaging in HTLV-1 infection is that of Okado et al. [22]
who undertook a retrospective review of computerised
tomography (CT) lung studies of 320 patients. Abnor-
malities, predominantly parenchymal, were reported in
98 patients (30.1 %) of which almost all had centrilobu-
lar nodules (95/320) and half had thickening of broncho-
vascular bundles (55/320), ground glass opacities (51/
320) and/or bronchiectasis (50/320; 15.6 %). The indica-
tions for CT are not detailed but in almost 1/3 the scan
was performed prior to the diagnosis of HTLV-1 infection.
Even higher rates (61.3 %) but similar abnormalities among
HTLV-1 infected ACs were reported from Okinawa [25].
Two additional studies of indigenous Australians have
shown an association between HTLV-1 infection and bron-
chiectasis [26, 27]. A central Australian case-control study
reported an association between HTLV-1 VL and bronchi-
ectasis. Despite much higher VL in the cases than the
matched controls this association is not maintained in the
multivariate analysis [26]. Further to this in a retrospective
study of indigenous Australians with bronchiectasis
HTLV-1 infection was associated with more extensive dis-
ease and more bronchiectasis-related deaths (OR 5.78
95 % CI 1.17 - 26.75, p 0.028) [28]. A causal association
between HTLV-1 and bronchiectasis has not been proven
and it is important to note that outside of Japan reports
relating to bronchiectasis concern Australian aborigines
living in Central Australia who are known to have distinct
socio-economic circumstances and health concerns that
also differ from many HTLV-1 infected populations. Sig-
nificantly in a prospective cohort study that included 152
HTLV-1 infected blood donors in the USA followed for a
median of 4.4 years no increase in respiratory infections
was found compared with the uninfected blood donors
[29]. It is therefore uncertain whether confounders exist
in either population which together with, or separately
from, HTLV-1 predispose to bronchiectasis. Given the as-
sociation between HTLV-1 VL and HTLV-1 associated
diseases, whether inflammatory, infectious or malignant
we postulated that if HTLV-1 is associated with an in-
creased risk of bronchiectasis, this would be more com-
mon in patients with high HTLV-1 VL. We therefore
conducted a retrospective study to describe the prevalence
of, and factors associated with, a formal diagnosis of
bronchiectasis.
Although HTLV-1 associated diseases are rare in the
UK the National Centre for Human Retrovirology man-
ages a relatively large HTLV cohort, the only one of its
kind in Europe. The cohort was initially established in
1993 to gain an understanding of the breadth and patho-
genesis of HTLV disease through longitudinal observation.
Despite the aforementioned reports HTLV-1 infected pa-
tients are not generally considered to be at greater risk of
bronchiectasis than the general population and therefore
chest imaging in our cohort has only been conducted if
there was a clinical suspicion of lung disease.
Methods
A single national centre retrospective case review of all
464 HTLV-1 seropositive patients attending the National
Centre for Human Retrovirology, St Mary’s Hospital,
London, UK between 1993 and 2012. Subjects were
characterised in regard to HTLV-1 infection as either
symptomatic patients (SP) or as ACs. SPs had an under-
lying disease with documented association with HTLV-1:
ATLL; strongyloidiasis; HAM/TSP; or other HTLV asso-
ciated inflammatory disease (HAID) namely polymyosi-
tis, uveitis and arthritis. Twenty-three patients were
excluded as they were co-infected with human immuno-
deficiency virus type 1. A further 28 patients were ex-
cluded as they had neurological features that could not
be classified as either HAM/TSP or polymyositis and it
was difficult to establish whether HTLV-1 infection was
causal or co-incidental and thus whether they had
underlying HTLV-1-associated disease.
The clinic database, case notes, laboratory and radi-
ology reports were examined. In accordance with the
guidance produced by the UK National Research Ethics
Service, research ethics approval was not required for this
study. Once the data were collated we used the clinical
code, which is separate from the hospital number, to ensure
confidentiality. Bronchiectasis was correlated with HTLV-1
symptoms and with concurrent HTLV-1 VL (this being the
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number of HTLV-1 DNA copies/100 PBMCs and reported
as VL %). Data were collated on the number of patients that
had CT i.e. CT chest or high resolution CT (HRCT), the
clinical indication for the imaging and the radiological find-
ings particularly the presence or absence of bronchiectasis.
A multi-detector CT scanner was used. The CTcriteria that
were used for diagnosis of bronchiectasis were bronchial
dilatation as evidence by bronchoarterial ratio greater than
1 to 1.5 (signet ring sign) and/or non-tapering airways (air-
ways visible within 1 cm of the visceral pleura, tramlines
and flaring). Indirect signs such as thickening of the bron-
chial wall, loss of lobe volume, mosaic perfusion pattern, a
tree-in- bud pattern, and mucus plugs were also used.
Data was also collected on risk factors for bronchiec-
tasis i.e. congenital conditions, tuberculosis, childhood
infection and exposure to chemical irritant. We also col-
lected data on the presence of other chronic conditions
i.e. chronic liver disease, myocardial disease, renal and
cardiac failure. Data were analysed by Student t-test,
relative risk (RR), Fisher’s exact test and backwards
multivariate logistic regression using commercial statis-
tics software (SPSS 21, SPSS Inc, Chicago). A p-value of
0.05 or less was considered significant.
Results
Four hundred and thirteen patients infected with
HTLV-1 were included comprising 246 ACs and 167
SPs. Of the 167 SPs: 54 had ATLL; 95 HAM/TSP; 11
HAID and 7 strongyloidiasis (Fig. 1). Fourteen (3.4 %),
were found on pulmonary CT to have previously un-
diagnosed bronchiectasis.
Although the majority of all subjects were of African/
Afro-Caribbean origin (300/413, 72.6 %), SPs were
significantly more likely to be of African/Afro-Caribbean
ethnicity (139/167, 83.2 %) than the ACs (161/246,
65.5 %, p < 0.0001) (Table 1) and this applied across all
the symptomatic subgroups: HAM/TSP 74/95 (77.9 %);
ATLL 48/54 (88.9 %); Strongyloidiasis 7/7 (100 %);
HAID 10/11 (91 %). SPs were older than ACs (median
age 54 vs. 44 years; p < 0.0001) but there was no differ-
ence in the time since HTLV-1 was diagnosed (i.e. dur-
ation of follow-up from first diagnosis; median years in
the SP 7.7 years; AC 7 years). There were fewer females
in the AC group (63:183) with a male to female ratio of
1:2.9 compared with 1:2.3 among the SPs (51:116) but
this was not significant (p = 0.27).
HTLV-1 VL, which was available for 167 SPs and 234
ACs, was significantly higher in SPs (median HTLV VL
15.9 % 95 % CI 13.7 – 20) compared with ACs (median
1.25 %; 95 % CI 0.82 – 1.69, p <0.0001). HTLV-1 VL
among non-HAM/TSP SPs was higher still (median
21.6 %, non-HAM/TSP vs. AC; p = 0.0001). The
median VLs in the different SP groups were: HAM/TSP
14 %, HAID 8.5 %, ATLL 29.3 % and Strongyloidiasis
20.6 % (Table 1).
Thirty four of 246 ACs and 30/167 SPs had a CT
chest. Of the CT scans performed, 4/34 (11.7 %) in the
AC group and 10/30 (33.3 %) in the SP group were high
resolution CTs. (HRCTs). The reasons for CT imaging
were productive cough +/- recurrent infection (50 %
ACs vs. 50 % SPs), weight loss (26.5 % ACs vs. 23.3 %
SPs), suspected malignancy (23.5 % ACs vs. 6.7 % SPs)
or an abnormal chest X-ray (SPs 16.7 %). The indication
for CT was unclear in 3.3 % SPs. The indications for
HRCT was productive cough +/- recurrent infection.
The time from HTLV-1 diagnosis to imaging was on
average 2.5 years in ACs and 2 years in SPs (Table 1).
Out of the total 64 patients that underwent CT imaging,
13 were Caucasian (13/90, 14 %) and 51 were Afro-
Caribbean (51/300, 17 %).
Fourteen patients were newly diagnosed with bronchi-
ectasis based on HRCT, (indications detailed in Table 1):
1/246 AC (0.4 %) and 13/167 SPs (2 with HAID, 1 with
ATLL, 10 with HAM/TSP) (7.8 %, RR 19.2 95 % CI 2.5-
14.5, p = 0.004). Bronchiectasis was more common in
those with HAM/TSP compared to non-HAM/TSP pa-
tients (10/95 vs. 4/318, RR 8.4 95 % CI 2.7-26.1, p =
0.0002). None of our patients had a history of significant
childhood infections as per the patient or their health re-
cords. We thereby did not identify the other causes of
bronchiectasis including congenital conditions, tubercu-
losis, exposure to chemical irritant or childhood infec-
tions. There were also no documented or clinical features
to suggest a diagnosis of bronchiectasis at or prior to the
diagnosis of HTLV-1 infection as per the patient or their
health records. We did not exclude alpha-1 antitrypsin de-
ficiency or autoimmune conditions however our patients
Fig. 1 Flow diagram demonstrating the breakdown of the HTLV-1
cohort into symptomatic patients and asymptomatic carriers
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had no other clinical symptoms or signs to suggest these
conditions. There was also no history of organ failure or
myocardial disease. All of our patients with bronchiectasis
were non-smokers. Through detailed history obtained
from the patients and their health records, they were diag-
nosed with bronchiectasis 1-3 years following their initial
HTLV-1 diagnosis and hence at least 1-3 years from any
initial symptoms of HTLV-1 infection.
The characteristics of the patients with bronchiectasis
are summarised in Table 2. The median HTLV-1 VL at
the time of diagnosis of bronchiectasis was 25.2 % in the
SPs and 3.1 % in the solitary AC. Although higher, the
median VL in HAM/TSP patients with bronchiectasis
was not significantly different from the remaining
HAM/TSP patients (25.2 % vs. 14 %, p = 0.72). Bronchi-
ectasis was more common amongst Caucasians (6.7 %;
6/20 SPs & 0/70 ACs) than African/Afro-Caribbean
(2.0 %; 5/137 SPs & 1/163 ACs, Fisher’s exact test p =
0.01). The relative risk of bronchiectasis from not being
African/Afro-Caribbean was 3.45 (1.2-9.7, p = 0.02).
There was no significant difference in age at presenta-
tion to the HTLV clinic diagnosis of HTLV-1 between
Table 1 Characteristics of the HTLV-1 cohort and the indications for CT imaging






South American 2 1
Not known 2 1
M:F ratio 51:116 1:2.9 p = 0.27





Time from HTLV diagnosis (years) to CT 2 2.5
Indication for CT imaging (bronchiectasis)
Productive cough +/- recurrent chest infection 15 (9) 17 (1)
Weight loss 7 9
Suspected malignancy 2 8
Abnormal chest X-ray 5 (4)
Unclear 1
Table 2 Characteristics of the HTLV-1 patients with a formal diagnosis of bronchiectasis
Symptomatic patients Asymptomatic carriers
Number of patients 13 1
Median age at 1st presentation (years) 59.3 50.9






Median HTLV-1 proviral load at diagnosis of bronchiectasis 25.2 % 3.07 %
Bilateral: unilateral bronchiectasis 11/2 1/0
Cylindrical: cystic bronchiectasis 11/2 1/0
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SPs with and without bronchiectasis (median 59.3 vs.
53.9 years, p = 0.43) nor between the patients with
HAM/TSP with and without bronchiectasis (median
59.5 vs. 54.7 years, p = 0.48).
In the multivariate analysis disease state (p < 0.001)
and ethnicity (p = 0.02) but not age, gender or HTLV-1
VL were independent predictors for bronchiectasis.
Discussion
Our data suggest that bronchiectasis is more common
among HTLV-1 infected subjects in the UK than among
the general population, that the inflammatory process of
HAM/TSP and other HAID is implicated in pathogen-
esis and that Caucasians infected with HTLV-1 may be
more susceptible to bronchiectasis than African/Afro-
Caribbeans.
Mass chest radiography during the 1950s indicated a
prevalence of 100 per 100,000 adult UK population of bron-
chiectasis [30]. The 3.4 % documented prevalence of bron-
chiectasis in our HTLV-1 cohort is higher than that reported
in general UK (0.1 %) or US populations (0.04-.0.27) [30, 31].
In the general population the prevalence of bronchiec-
tasis increases with age. A retrospective cohort study in
the US found the prevalence of bronchiectasis to be 4.2
per 100,000 population aged 18-34 years and 271.8 per
100,000 population aged >75 [30]. However age was not
an independent variable in this cohort, nor is the cohort
particularly old (median age 48.6 years).
Another consideration is the ethnic bias of the cohort
which is predominantly of African/Afro-Caribbean eth-
nicity. However not being African/Afro-Caribbean car-
ried a greater than 3 fold increased risk for diagnosed
bronchiectasis. Cohort data from the two Caucasian
populations with highest HTLV-1 prevalence, Iran and
Romania have not been reported. Whilst the lower risk
of bronchiectasis observed in African/Afro-Caribbean
subjects merits further investigation this may account
for the paucity reports of association between HTLV-1
and bronchiectasis from outside of Japan. Genetics, tim-
ing of primary infection and environmental factors may
all contribute to these different rates. Difference in bron-
chiectasis rates amongst different ethnicities have been
reported from New Zealand and Fiji between Polynesian
and Non-Polynesian and Melanesian and Indian children
respectively [32, 33]. Whilst the underlying cause of
bronchiectasis has also been shown to be influenced by
ethnicity [34].
We hypothesised that HTLV-1 VL would be associated
with bronchiectasis and as previously reported for this co-
hort, and consistent with other studies, HTLV-1 VL was
significantly higher in patients with symptomatic HTLV-1
infection than in the ACs [18]. However although HTLV-
1 VL was high in all the patients with bronchiectasis, in-
cluding the subject previously characterised as AC, an
association between bronchiectasis and high HTLV-1 VL
was not found in the multivariate analysis whereas pre-
existent disease was strongly associated suggesting that
prior inflammatory disease (HAM/TSP or HAID) rather
than VL per se was the key association. This theory is fur-
ther supported by the median VL in the SPs with bronchi-
ectasis not being significantly higher than the VL reported
for all SPs (25.2 % SPs with bronchiectasis, 15.90 % all SPs
p = 0.62), even when the patients with ATLL (who gener-
ally have the highest VLs) were excluded (14 %; p = 0.067).
This suggests that whilst high VL may be essential it is not
sufficient for the development of bronchiectasis. This is
further supported by the association of bronchiectasis
with HAM/TSP rather than ATLL pointing to a key role
of inflammation rather than immune suppression in the
aetiology, although both may co-exist and the course of
ATLL may be too short or too severe to result in bronchi-
ectasis. However, since ATLL is thought to follow many
decades of HTLV-1 infection, occurs later than HAM/
TSP and against a background of pre-existing high VL this
again points to inflammation secondary to high VL, rather
than VL per se in the pathogenesis of HTLV-1-associated
bronchiectasis.
Our HTLV-1 cohort is comprised of patients from the
three main categories of infection, namely asymptomatic
carriage, ATLL and HAM/TSP and, as reflects the
demographics of HTLV-1 infection in the UK, was predom-
inantly of African/Afro-Caribbean ethnicity. The high
number of patients that were Caucasian in the AC group is
secondary to universal blood donor screening. The M: F
ratio between ACs and SPs was similar. A major cause for
bronchiectasis is early childhood infections. This can be
difficult to exclude however there was no significant child-
hood infections reported by the patient or in their health
records. Further to this even though we did not test for
autoimmune conditions or alpha 1 antitrypsin deficiency
our patients had no clinical symptoms or signs of these
conditions.
The pathogenesis of bronchiectasis associated with
HTLV-1 has not been studied. The association here with a
prior diagnosis of another inflammatory disease and the
prominent lymphocytosis in BAL reported by others [19,
21] points to the same inflammatory state that causes
HAM/TSP. Another possibility is that HTLV-1 causes a
degree of local immune suppression (perhaps akin to
infective dermatitis) which makes the patient prone to low
grade pulmonary infections which in turn predisposes
them to complications particularly bronchiectasis. The
most striking example of HTLV-associated immune
impairment is seen in the relationship between HTLV-1
infection and Strongyloides stercoralis, with a higher
incidence HTLV-1 amongst S. stercoralis carriers [35], and
a higher incidence of strongyloidiasis in HTLV-1 seroposi-
tive patients than in HTLV-1 negative individuals [36].
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Strengths and limitations of this study
The major limitation of this study is is that CT imaging
had only been performed if the patient had clinical or
radiological features that raised the suspicion of under-
lying pulmonary disease with no lower threshold for im-
aging in this cohort compared to the general population.
Thus only 15 % of the cohort had CT imaging (13.8 %
ACs and 18.0 % SPs) and the prevalence of bronchiec-
tasis, particularly early/mild or asymptomatic, may have
been underestimated. Second, the number of cases of
bronchiectasis is relatively few. Despite this the associa-
tions reported are statistically robust, suggesting that
these are not chance findings. Third, we have no data on
the effect of HTLV-1 or associate inflammatory cells in
the lung and can only speculate regarding pathogenesis.
The relative strengths are studying a population that is
socially and ethnically distinct and the median seven
years follow-up of each patient group. A prospective
study is now justified to confirm and extend these find-
ings on the frequency of bronchiectasis in patients with
HTLV particularly amongst those with pre-existing
HTLV-associated disease and to explore pathogenesis.
Conclusion
In the UK bronchiectasis is more common amongst HTLV-
1 infected subjects (3.4 %) than reported for the general
population (0.1 %). Non-African/Afro-Caribbean patients
with pre-existing HTLV-1-associated disease are most at
risk. Our data support the view that the spectrum of HTLV-
1-associated disease is broader than previously thought and
that disseminated mild inflammation may be common, al-
beit asymptomatic. Our results emphasise the importance of
screening symptomatic HTLV-1 patients for pulmonary dis-
ease (i.e. radiological imaging) early following diagnosis of
HTLV-1 and that CT imaging should be requested even in
the presence of minimal symptoms. Furthermore HTLV ser-
ology should be considered in all patients with bronchiec-
tasis in whom no other cause is apparent.
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